Farmas USA

A puntito de romper los 9.000....con el empujoncito de kowa,los 12 k van a quedarse cortos :)

GSK es la que vacunara contra el ebola...no se como resultara...no lo tenian muy avanzado

una grande, como no ... pero era la que lo tenia en fase I.

GSK

NVAX

de un usano

aezs

está pidiendo un corto o tiene catalizadores?, especialista en diluir a las mínima subida, para ello es una de las más odiadas.

sp500

quien se pone corto en 2004?

si, por o que lei por ahi, TKMR esta mucho mas avanzada que ellos, no entiendo el porque, nunca lei tanto ingles jejejej ¡EL MUNDO DE LAS FARMAS EEUU MOLA!

EDITO: primer caso de ebola en senegal, recordemos que de alli tenemos muchos inmigrantes
http://www.breakingnews.com/topic/africa-ebola-outbreak-2014/

ACTCD

Artículo bajista desinformardo en hotstocks. No vale la pena leerlo, pero lo pego. Lo han colgado en el foro sin el link.

New Hotstocked article. Surprise! Still garbage.

Not posting a link. I don't even REALLY recommend reading it, as it is an obvious hook.
"
After the reverse stock split came into effect yesterday, the inevitable followed for Advanced Cell Technology, Inc. (ACTC) or currently (OTCQB:ACTCD)) as the the fifth symbol will remain for a month to signalize the split. Time and time again we've seen penny stocks who initiate a RSS immediately start falling in price, in this instance 3.8% or from $8.15 to $7.84. The dollar volume remained strong at 1.45 million, but general investor sentiments on forums show quite the lack of enthusiasm for the situation.

We've seen this before, they say." The REAL reason for reverse stock splits is to crank up the printing press and dilute more." This is just one example of many similar negative thoughts. Others include musings that reverse splits are commonly a last resort for companies who are financially "check" and one move away from "mate."

On the other hand there are those who still believe in ACTC – and the company will sorely need them in the coming days, as the price will likely continue its descent. These people cling to the hope that the CEO, Mr. Paul Wotton, has a plan for a strategic partnership or that a buy-out would soon uplist ACTC to the NASDAQ exchange.

Is that hope even realistic, however, is the bitter question? Nothing suggests such a thing. The company continues to be affiliated with Lincoln Capital, viewed by most as toxic funders. A quick look at the fundamentals of ACTC dissipates notions that it can offer anything to investors. As one user put it, someone needs to buy between $60 and $80 million in shares for the uplisting (as per the $55 million Shareholder Equity Value condition of the NASDAQ Listing Review Committee). Some of the main points of the last financial report include:

$4 million in Cash a/o June 30,2014
$4.6 million in Total Current Assets
$9.4 million in Total Current Liabilities
$15.5 million in Net Loss
On top of that the Net Loss is not only large for the scale of the company, but it also seems to be becoming bigger each quarter. For the first quarter of this year it was $8.7 million. Would any private investor be tempted to buy in a company who is only in Phase 1 of clinical trials for its products? Phase 2 and 2b usually take years to go through; ACTC hasn't even reached that stage.

For now though perhaps there is still breathing room, as the deals with Lincoln Capital will at least keep the company afloat. For how long? Only the future will tell."

Aezs

Los usanos hablan de dilución pero esta en medio de una. Hizo una ATM hace un par de meses y no ha anunciado su finalización. PDFUA en noviembre